Activating ESR1 mutations differentially impact the efficacy of ER antagonists

Recent studies have identified somatic ESR1 mutations in patients with metastatic breast cancer (MBC) and found some of them to promote estrogen-independent activation of the receptor. The degree to which all recurrent mutants can drive estrogen-independent activities and reduced sensitivity to ER a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Toy, Weiyi, Weir, Hazel, Razavi, Pedram, Lawson, Mandy, Goeppert, Anne U, Mazzola, Anne Marie, Smith, Aaron, Wilson, Joanne, Morrow, Christopher, Wong, Wai Lin, De Stanchina, Elisa, Carlson, Kathryn E., Martin, Teresa S., Uddin, Sharmeen, Li, Zhiqiang, Fanning, Sean, Katzenellenbogen, John A., Greene, Geoffrey, Baselga, Jośe, Chandarlapaty, Sarat
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5340622/
https://ncbi.nlm.nih.gov/pubmed/27986707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-1523
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados